John Inge Johnsen

Medulloblastoma and neuroblastoma are tumors that develop in the nervous system and are the most common solid tumors in children. Often the tumors respond poorly to the treatment given and the mortality rate is high. The need to develop more effective treatment is great. Solid tumors can be considered heterogeneous entities consisting of tumor cells with different degrees of differentiation or maturity. Individual cells in these tumors resemble normal stem cells in the body, with the ability to renew themselves while simultaneously maturing and developing into different cell types. From a treatment point of view, these cells are important as they are resistant to various treatments. The project aims to identify new molecules for targeted therapy and to characterize the microenvironment in medulloblastoma and neuroblastoma, with the goal of developing more effective therapies. To make this possible, increased knowledge of the tumor cell's molecular pathology is required. By using molecular biological techniques to study how medulloblastoma and neuroblastoma cells differ from normal cells in the nervous system and how the tumor cells contribute to the establishment of a microenvironment that favors tumor formation, we hope to find molecular signatures specific to tumor cells and to find specific drugs that kill these cells . We want to find new molecular targets for therapy that can lead to better survival and fewer side effects for children with medulloblastoma and neuroblastoma. We want to try to understand how the cancer cell interacts with the surrounding normal cells and how a microenvironment that supports the tumor's growth and spread arises. The ultimate goal is to cure the majority of children with medulloblastoma and neuroblastoma.

Medulloblastoma and neuroblastoma are tumors that develop in the nervous system and are the most common solid tumors in children. The tumors often respond poorly to the treatment given, and mortality is high. The need to develop more efficient treatment is great. Solid tumors can be considered as heterogeneous entities including tumor cells with varying degrees of differentiation or maturity. Single cells in medulloblastoma are similar to normal stem cells in the body, with the ability to renew themselves and at the same time mature and develop into different cell types. From a therapeutic point of view, these cells are of importance as they are resistant to various treatments. The project aims to identify new molecules for targeted therapy and to characterize the microenvironment in medulloblastoma and neuroblastoma, with the aim of developing more effective therapies. To enable this, extended knowledge of the tumor cell's molecular pathology is required. When using molecular biological techniques to study how medulloblastoma and neuroblastoma cells differ from normal cells in the nervous system and how the tumor cells contribute to the establishment of microenvironment that benefits tumor formation, we hope to find molecular signatures specific to tumor cells and to find specific drugs that kill these cells. The ultimate goal is to find new molecular targets for therapy that can lead to better survival and less side effects for children with medulloblastoma and neuroblastoma. We want to try to understand how the cancer cell interacts with the surrounding normal cells and how a microenvironment that supports the growth and spread of the tumor occurs.

Medulloblastoma and neuroblastoma are tumors that develop in the nervous system and are the most common solid tumors in children. The tumors often respond poorly to the treatment given, and mortality is high. The need to develop more efficient treatment is great. Solid tumors can be considered as heterogeneous entities including tumor cells with varying degrees of differentiation or maturity. Single cells in medulloblastoma are similar to normal stem cells in the body, with the ability to renew themselves and at the same time mature and develop into different cell types. From a therapeutic point of view, these cells are of importance as they are resistant to various treatments. The project aims to identify new molecules for targeted therapy and to characterize cancer stem cells in medulloblastoma and neuroblastoma, with the aim of developing more effective therapies. To enable this, extended molecular knowledge of the tumor cell's molecular pathology is required. When using molecular biological techniques to study how medulloblastoma and neuroblastoma cells differ from normal cells in the nervous system and how the tumor cells contribute to the establishment of microenvironment that benefits tumor formation, we hope to find molecular signatures specific to tumor cells and to find specific drugs that kill these cells. . The ultimate goal is to find new molecular targets for therapy that can lead to better survival and less side effects for children with medulloblastoma and neuroblastoma. We want to try to understand how the cancer cell interacts with the surrounding normal cells and how a microenvironment that supports the growth and spread of the tumor occurs. We also want to try to characterize cancer stem cells in these child tumors and find new treatments that are specifically corrected for these cells.

Medulloblastoma and neuroblastoma are tumors that develop in the nervous system and are the most common solid tumors in children. The tumors often respond poorly to the treatment given, and mortality is high. The need to develop more efficient treatment is great. Solid tumors can be considered as heterogeneous entities including tumor cells with varying degrees of differentiation or maturity. Single cells in medulloblastoma are similar to normal stem cells in the body, with the ability to renew themselves and at the same time mature and develop into different cell types. From a therapeutic point of view, these cells are of importance as they are resistant to various treatments. The project aims to identify new molecules for targeted therapy and to characterize cancer stem cells in medulloblastoma and neuroblastoma, with the aim of developing more effective therapies. To enable this, extended molecular knowledge of the tumor cell's molecular pathology is required. When using molecular biological techniques to study how medulloblastoma and neuroblastoma cells differ from normal cells in the nervous system and how the tumor cells contribute to the establishment of microenvironment that benefits tumor formation, we hope to find molecular signatures specific to tumor cells and to find specific drugs that kill these cells. . The ultimate goal is to find new molecular targets for therapy that can lead to better survival and less side effects for children with medulloblastoma and neuroblastoma. We want to try to understand how the cancer cell interacts with the surrounding normal cells and how a microenvironment that supports the growth and spread of the tumor occurs. We also want to try to characterize cancer stem cells in these child tumors and find new treatments that are specifically corrected for these cells.

Medulloblastoma and neuroblastoma are tumors that develop in the nervous system and are the most common solid tumors in children. The tumors often respond poorly to the treatment given, and mortality is high. The need to develop more efficient treatment is great. Solid tumors can be considered as heterogeneous entities including tumor cells with varying degrees of differentiation or maturity. Single cells in medulloblastoma are similar to normal stem cells in the body, with the ability to renew themselves and at the same time mature and develop into different cell types. From a therapeutic point of view, these cells are of importance as they are resistant to various treatments. The project aims to identify new molecules for targeted therapy and to characterize cancer stem cells in medulloblastoma and neuroblastoma, with the aim of developing more effective therapies. To enable this, extended molecular knowledge of the tumor cell's molecular pathology is required. When using molecular biological techniques to study how medulloblastoma and neuroblastoma cells differ from normal cells in the nervous system and how the tumor cells contribute to the establishment of microenvironment that benefits tumor formation, we hope to find molecular signatures specific to tumor cells and to find specific drugs that kill these cells. . The ultimate goal is to find new molecular targets for therapy that can lead to better survival and less side effects for children with medulloblastoma and neuroblastoma. We want to try to understand how the cancer cell interacts with the surrounding normal cells and how a microenvironment that supports the growth and spread of the tumor occurs. We also want to try to characterize cancer stem cells in these child tumors and find new treatments that are specifically corrected for these cells.

Medulloblastoma is an embryonic tumor that develops in the central nervous system and is the most common brain tumor in children. In many cases, the tumors respond poorly to the treatment given and mortality is high. In addition, today's treatment often causes severe physical and cognitive problems for the patient. There is therefore a great need to develop more efficient treatments. The project aims to identify new molecules for targeted therapy and to characterize cancer stem cells in medulloblastoma. A subpopulation of cells in the tumor has features similar to those of normal stem cells in the body, with the ability to renew themselves and at the same time mature and develop into different cell types. Cancer stem cells are believed to have the capacity to establish and drive cancer development. From a therapeutic point of view, these cells are probably of great importance as they have proved very resistant to various treatments. To enable the development of more effective therapies, increased molecular knowledge of tumor cells with stem cell properties is required. The ultimate goal of developing more effective therapies based on biological understanding for children with medulloblastoma. In using molecular biological techniques to study how medulloblastoma cells differ from normal cells in the brain, we hope to find molecular signatures specific to different subgroups of medulloblastoma and to be able to recapitulate these in preclinical models. This allows to find new molecular targets for therapy that can lead to better survival and less side effects for children with medulloblastoma.